Similarly, among the Crohn's cohort, the low dose achieved an endoscopic remission in 26.1% of patients, versus 13% with placebo, rising to 47.8% with the high dose and 34.8% for the matched control.

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...

One of the major lead-up events to the iconic Group 1 Melbourne Cup (3200m) over the two miles at Flemington on the first Tuesday of November, the Geelong Cup is targeted by foreign raiders and local ...